The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis

Summary

This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).

Timeline

Start

2008-01

Primary completion

2009-06

Completion

2009-06

Outcome

Met primary endpoint

paper Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). PMID 20693248 ↗

Publications

• Results Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 2011 Apr;37(4):806-12. doi: 10.1183/09031936.00072510. Epub 2010 Aug 6.
• Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD001127. doi: 10.1002/14651858.CD001127.pub5.

Drugs

Indications